Literature DB >> 3202908

Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy.

B E Harris1, R L Song, Y J He, S J Soong, R B Diasio.   

Abstract

The activity of dihydropyrimidine dehydrogenase (DPD), the initial, rate-limiting enzyme in pyrimidine catabolism, was measured at various times over a 24-hr period in the livers of rats housed under standardized conditions of light and dark. Under "normal" conditions, i.e. lights on from 6:00 a.m. to 6:00 p.m. and off from 6:00 p.m. to 6:00 a.m., a circadian rhythm of DPD activity was observed (P less than 0.0001, Cosinor analysis) with the peak of activity at 4:00 p.m. (2.96 nmol catabolites/min/mg) and the trough at 4:00 a.m. (0.40 nmol catabolites/min/mg). Maximum enzyme activity exceeded minimum activity by more than 7-fold. Reversing the light-dark cycle (i.e. lights on from 6:00 p.m. to 6:00 a.m. and off from 6:00 a.m. to 6:00 p.m.) resulted in a corresponding shift in enzyme activity. Under these "reverse" conditions, a circadian rhythm was observed (P less than 0.0001, Cosinor analysis) with the peak of activity at 6:00 a.m. (2.87 nmol catabolites/min/mg) and the trough at 6:00 p.m. (0.92 nmol catabolites/min/mg). These studies demonstrated that DPD activity in rat liver varies over a 24-hr period in association with the light-dark cycle.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3202908     DOI: 10.1016/0006-2952(88)90349-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

Review 1.  Chronopharmacokinetics of ciclosporin and tacrolimus.

Authors:  Massimo Baraldo; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  Can pharmacokinetic monitoring improve clinical use of fluorouracil?

Authors:  A M Young; S Daryanani; D J Kerr
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

3.  Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase.

Authors:  R B Diasio
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

4.  Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients.

Authors:  G A Bjarnason; I G Kerr; N Doyle; M Macdonald; M Sone
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.

Authors:  Hao Jiang; Jing Lu; Jiang Ji
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

6.  Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats.

Authors:  Shinji Kobuchi; Yukako Ito; Kae Okada; Kazuki Imoto; Kanji Takada
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-11-30       Impact factor: 2.441

Review 7.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

8.  CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNA in mouse liver.

Authors:  M Shimizu; T Tamura; Y Yamada; Y Akiyama; N Saijo; K Nishio
Journal:  Jpn J Cancer Res       Date:  2001-05

9.  DPD status and fluoropyrimidines-based treatment: high activity matters too.

Authors:  Emmanuel Chamorey; Eric Francois; Marie-Christine Etienne; Jean-Marc Ferrero; Frederic Peyrade; Emmanuel Barranger; Alexandre Bozec; Rémy Largillier; Ophelie Cassuto; Julien Viotti; Renaud Schiappa; Gérard Milano
Journal:  BMC Cancer       Date:  2020-05-18       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.